Another ray of hope emerges as US Centers for Disease Control and Prevention (CDC) approves Johnson & Johnson’s single-shot COVID-19 vaccine to be safe for use in individuals 18 years of age and older. J&J and the FDA have planned to alert doctors and vaccine recipients of the potential but exceedingly rare risks of thrombosis with thrombocytopenia syndrome (TTS), by adding it to the vaccine label and the FDA emergency use authorization fact sheet. The overall rate of clotting events is reported as 1.9 cases per million people by this vaccine.

The decision comes as a potential opportunity to reach millions of vulnerable groups who need the one-shot vaccine the most including ones who are difficult to reach twice, like the homeless or the disabled.

The vaccine utilizes a recombinant, replication-incompetent human adenovirus type 26 (Ad26) vector intended to encode a stabilized form of SARS-CoV-2 spike (S) protein, Contrasting the Pfizer and Moderna vaccines which utilize a different mechanism that relies on mRNA. But the decision of choosing the correct vaccination for an individual should be left with their healthcare provider.

The J&J vaccine is reported to be 66% effective overall in preventing moderate-to-severe COVID-19, 28 days after vaccination. It can be stored in normal fridge temperatures of 2–8°C (36–46°F) unlike other vaccines that require ultracold temperatures.

Source: https://specialty.mims.com/topic/covid-19-single-shot-vax-cleared-for-use-again?channel=multi-specialty&elq_mid=55618&elq_cid=42720